Recent Updates
Recently added Catalysts

PG-102

Phase 1

Obesity | Small molecule | Metabolic |Rani Therapeutics Holdings, Inc.|Last Updated: Mar 23, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06891287An Early Phase Study of RT-114PHASE1 NOT YET_RECRUITING 60May 1, 2025Mar 1, 2026Mar 23, 2025 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesityCOMBINATION_PRODUCTRT-114 is the RaniPill capsule with PG-102 for the treatment of obesity.
PG-102DRUGPG-102 is a drug for the treatment of obesity.
PlaceboOTHERThe placebo is the RaniPill with saline instead of a drug.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06891287studyFirstPostDate: changed